Tumor cell PD-L1 expression remains the cornerstone of the NSCLC treatment algorithm and the only immune-related predictive biomarker recommended by the European Society for Medical Oncology in the selection of patients who would benefit from PD-1/PD-L1 inhibitors [6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.